The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Silva AFG, Melro LMG, Besen BAMP, Mendes PV, Park M

Sulfonamide-induced acute eosinophilic pneumonia requiring extracorporeal membrane oxygenation support: a case report.

Critical care science. 2023;35(2):239-242

French AJ, Weller CV

Interstitial Myocarditis Following the Clinical and Experimental Use of Sulfonamide Drugs.

The American journal of pathology. 1942;18(1):109-21

Parry SD, Barbatzas C, Peel ET, Barton JR

Sulphasalazine and lung toxicity.

The European respiratory journal. 2002;19(4):756-64

Gascard E, Boutin C, Cargnino P, Girbal JP

[Labile infiltrate induced by a long-acting sulfonamide].

Marseille medical. 1969;106(11):891-3

Fiegenberg DS, Weiss H, Kirshman H

Migratory pneumonia with eosinophilia associated with sulfonamide administration.

Archives of internal medicine. 1967;120(1):85-9

Yamakado S, Yoshida Y, Yamada T, Kishida T, Kobayashi M, Nomura T

Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature.

Internal medicine (Tokyo, Japan). 1992;31(1):108-13